ArticleEuropean radiology2026
Predictive factors of axillary pathological complete response in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reply to the Letter to the Editor: Predictive factors of axillary pathological complete response in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy.European radiology · 2026Article
- Letter to the Editor: Axillary radiological complete response in HER2-positive breast cancer: toward validated decision support.European radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAxillary lymph node dissection (ALND) is associated with significant morbidity in breast cancer patients. In HER2-positive (HER2+) breast cancer, neoadjuvant chemotherapy (NAC) combined with anti-HER2 therapy can achieve high rates of pathological complete response (pCR), supporting the de-escalation of axillary surgery. Identifying reliable predictors of axillary pCR is essential for safely omitting ALND in selected patients. MATERIALS AND
methodsThis retrospective cohort study included 60 women with HER2+ breast cancer and axillary involvement treated with NAC followed by surgery between 2015 and 2022. All patients had pre- and post-treatment mammography, ultrasound, and MRI. The variables analyzed included age, Ki-67 index, hormone receptor status, breast and axillary radiological and pathological response (rCR, pCR), number of suspicious lymph nodes, and type of axillary surgery. Univariate and multivariate logistic regression models were performed to identify independent predictors of axillary pCR.
resultsAxillary pCR was achieved in 85% of patients. On univariate analysis, axillary rCR (OR = 5.83; 95% CI: 1.30-26.12; p = 0.021) and breast rCR (OR = 6.79; 95% CI: 1.27-36.34; p = 0.025) were significantly associated with axillary pCR. Multivariate analysis identified axillary rCR (OR = 17.98; 95% CI: 1.43-225.93; p = 0.025) and Ki-67 index (OR = 0.90; 95% CI: 0.82-0.99; p = 0.045) as independent predictors of axillary pCR.
conclusionsAxillary rCR and Ki-67 are independent predictors of axillary pCR in HER2+ breast cancer patients treated with NAC. These findings may help optimize axillary management and support less invasive approaches. Further multicenter studies should validate predictive models and refine imaging criteria for axillary response assessment. KEY POINTS: QuestionIdentifying predictive factors for axillary pCR in HER2+ breast cancer patients undergoing NAC. FindingsAxillary radiological complete response predicted axillary pCR in univariate (p = 0.021) and multivariate analyses (p = 0.025), while Ki-67 was marginally significant in the multivariate model (p = 0.045). Clinical relevanceRecognizing reliable predictors of axillary pCR may support the omission of ALND in selected HER2+ patients, minimizing surgical morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.